BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover - 2Smartwatches: Remain Associated and Dynamic
- 3The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- 4Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- 5Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- French ship crosses Strait of Hormuz in first Western European transit during Iran war
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- The most effective method to Involve Handshakes for Compromise and Compromise
- EU states agree first step for Ukraine reparations fund
- US measles cases surpass 2,000, highest in 30 years: CDC
- Japan deploys the military to counter a surge in bear attacks
- We may be witnessing the messy death of a star in real time
- Barn Stored Lotus Esprit Turbo Seen After 30 Years
- After toilet and email issues, Artemis II astronauts fire engine to head for the moon
